Inhibitory effect of valsartan on the intestinal absorption and renal excretion of bestatin in rats

Journal of Pharmaceutical Sciences

Volumn 103, Issue 2, 2014, Pages 719-729

  Huo, Xiaokui ^a   Liu, Qi ^a   Wang, Changyuan ^a   Meng, Qiang ^a   Sun, Huijun ^a   Peng, Jinyong ^a   Ma, Xiaochi ^a   Sun, Pengyuan ^a   Liu, Kexin ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Drug interaction; Intestinal absorption; Organic anion transporters; Peptide transporters; Pharamcokinetics; Renal excretion

Indexed keywords

BESTATIN; EPROSARTAN; IRBESARTAN; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 3; PEPTIDE TRANSPORTER 1; TELMISARTAN; VALSARTAN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG UPTAKE; HELA CELL; IC 50; INTESTINE ABSORPTION; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY EXCRETION;

DRUG INTERACTION; INTESTINAL ABSORPTION; ORGANIC ANION TRANSPORTERS; PEPTIDE TRANSPORTERS; PHARAMCOKINETICS; RENAL EXCRETION;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ALGORITHMS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CELLS, CULTURED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG INTERACTIONS; HEK293 CELLS; HELA CELLS; HUMANS; INTESTINAL ABSORPTION; LEUCINE; MALE; ORGANIC ANION TRANSPORT PROTEIN 1; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; RATS; RATS, WISTAR; SYMPORTERS; TANDEM MASS SPECTROMETRY; TETRAZOLES; VALINE;

EID: 84895922635     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23805     Document Type: Article

References (35)

1. International Transporter Consortium. 2010. Membrane transporters in drug development. Nat Rev Drug Discov 9:215-236.
2. Zhang J, Wang C, Liu Q, Meng Q, Cang J, Sun H, Gao Y, Kaku T, Liu K. 2010. Pharmacokinetic interaction between JBP485 and cephalexin in rats. Drug Metab Dispos 38:930-938.
3. Gupta D, Varghese Gupta S, Dahan A, Tsume Y, Hilfinger J, Lee KD, Amidon GL. 2013. Increasing oral absorption of polar neuraminidase inhibitors: A prodrug transporter approach applied to oseltamivir analogue. Mol Pharm 10:512-522.
4. Liu T, Meng Q, Wang C, Liu Q, Guo X, Sun H, Peng J, Ma X, Kaku T, Liu K. 2012. Changes in expression of renal Oat1, Oat3 and Mrp2 in cisplatin-induced acute renal failure after treatment of JBP485 in rats. Toxicol Appl Pharmacol 264:423-430.
5. Guo X, Meng Q, Liu Q, Wang C, Mao Q, Sun H, Peng J, Kaku T, Liu K. 2012. Peptide cotransporter 1 in intestine and organic anion transporters in kidney are targets of interaction between JBP485 and lisinopril in rats. Drug Metab Pharmacokinet 27:232-241.
6. Morrissey KM, Stocker SL, Wittwer MB, Xu L, Giacomini KM. 2013. Renal transporters in drug development. Annu Rev Pharmacol Toxicol 53:503-529.
7. Müller F, Fromm MF. 2011. Transporter-mediated drug-drug interactions. Pharmacogenomics 12:1017-1037.
8. Ye J, Liu Q, Wang C, Meng Q, Peng J, Sun H, Kaku T, Liu K. 2012. Inhibitory effect of JBP485 on renal excretion of acyclovir by the inhibition of OAT1 and OAT3. Eur J Pharm Sci 47:341-346.
9. Xu Q, Wang C, Meng Q, Liu Q, Sun H, Peng J, Ma X, Kaku T, Liu K. 2013. OAT1 and OAT3: Targets of drug-drug interaction between entecavir and JBP485. Eur J Pharm Sci 48:650-657.
10. Lkhagvaa B, Tani K, Sato K, Toyoda Y, Suzuka C, Sone S. 2008. Bestatin, an inhibitor for aminopeptidases, modulates the production of cytokines and chemokines by activated monocytes and macrophages. Cytokine 44:386-391.
11. Terada T, Saito H, Inui K. 1998. Interaction of beta-lactam antibiotics with histidine residue of rat H+/peptide cotransporters, PEPT1 and PEPT2. J Biol Chem 273:5582-5585.
12. Zhu Y, Meng Q, Wang C, Liu Q, Sun H, Kaku T, Liu K. 2012. Organic anion transporters involved in the excretion of bestatin in the kidney. Peptides 33:265-271.
13. Hori R, Tomita Y, Katsura T, Yasuhara M, Inui K, Takano M. 1993. Transport of bestatin in rat renal brush-border membrane vesicles. Biochem Pharmacol 45:1763-1768.
14. Grujić M, Renko M. 2002. Aminopeptidase inhibitors bestatin and actinonin inhibit cell proliferation of myeloma cells predominantly by intracellular interactions. Cancer Lett 182:113-119.
15. Nakanishi T, Tamai I, Takaki A, Tsuji A. 2000. Cancer cell-targeted drug delivery utilizing oligopeptide transport activity. Int J Cancer 88:274-280.
16. Knütter I, Kottra G, Fischer W, Daniel H, Brandsch M. 2009. High-affinity interaction of sartans withH+/peptide transporters. Drug Metab Dispos 37:143-149.
17. Sato M, Iwanaga T, Mamada H, Ogihara T, Yabuuchi H, Maeda T, Tamai I. 2008. Involvement of uric acid transporters in alteration of serum uric acid level by angiotensin II receptor blockers. Pharm Res 25:639-646.
18. Bindschedler M, Degen P, Flesch G, de Gasparo M, Preiswerk G. 1997. Pharmacokinetic and pharmacodynamic interaction of single oral doses of valsartan and furosemide. Eur J Clin Pharmacol 52:371-378.
19. Jiang J, Tian L, Huang Y, Xie S, Xu L, Liu H, Li Y. 2011. Pharmacokinetic profiles of hydrochlorothiazide alone and in combination with benazepril or valsartan in healthy Chinese volunteers: Evaluation of the potential interaction. Int J Clin Pharmacol Ther 49:756-764.
20. Lill J, Bauer LA, Horn JR, Hansten PD. 2000. Cyclosporine-drug interactions and the influence of patient age. Am J Health Syst Pharm 57:1579-1584.
21. Yan YD, Sung JH, Kim KK, Kim DW, Kim JO, Lee BJ, Yong CS, Choi HG. 2012. Novel valsartan-loaded solid dispersion with enhanced bioavailability and no crystalline changes. Int J Pharm 422:202-210.
22. Bae SK, Kim MJ, Shim EJ, Cho DY, Shon JH, Liu KH, Kim EY, Shin JG. 2009. HPLC determination of irbesartan in human plasma: Its application to pharmacokinetic studies. Biomed Chromatogr 23:568-572.
23. Caballero R, Delpón E, Valenzuela C, Longobardo M, González T, Tamargo J. 2001. Direct effects of candesartan and eprosartan on human cloned potassium channels involved in cardiac repolarization. Mol Pharmacol 59:825-836.
24. Shen J, Jiao Z, Li ZD, Shi XJ, Zhong MK. 2005. HPLC determination of telmisartan in human plasma and its application to a pharmacokinetic study. Pharmazie 60:418-420.
25. Sawafuji K, Miyakawa Y, Weisberg E, Griffin JD, Ikeda Y, Kizaki M. 2003. Aminopeptidase inhibitors inhibit proliferation and induce apoptosis of K562 and STI571-resistant K562 cell lines through the MAPK and GSK-3beta pathways. Leuk Lymphoma 44:1987-1996.
26. Gonzalez O, Iriarte G, Rico E, Ferreirós N, Maguregui MI, Alonso RM, Jiménez RM. 2010. LC-MS/MS method for the determination of several drugs used in combined cardiovascular therapy in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 878:2685-2692.
27. Liu Z, Wang C, Liu Q, Meng Q, Cang J, Mei L, Mei L, Kaku T, Liu K. 2011. Uptake, transport and regulation of JBP485 by PEPT1 in vitro and in vivo. Peptides 32:747-754.
28. Wang W, Liu Q, Wang C, Meng Q, Kaku T, Liu K. 2011. Effects of JBP485 on the expression and function of PEPT1 in indomethacin-induced intestinal injury in rats and damage in Caco-2 cells. Peptides 32:946-955.
29. Hasannejad H, Takeda M, Taki K, Shin HJ, Babu E, Jutabha P, Khamdang S, Aleboyeh M, Onozato ML, Tojo A, Enomoto A, Anzai N, Narikawa S, Huang XL, Niwa T, Endou H. 2004. Interactions of human organic anion transporters with diuretics. J Pharmacol Exp Ther 308:1021-1029.
30. Yamashiro W, Maeda K, Hirouchi M, Adachi Y, Hu Z, Sugiyama Y. 2006. Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin IIAT1-receptor, in humans. Drug Metab Dispos 34:1247-1254.
31. Iwanaga T, Sato M, Maeda T, Ogihara T, Tamai I. 2007. Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter. J Pharmacol Exp Ther 320:211-217.
32. Tachibana T, Kato M, Watanabe T, Mitsui T, Sugiyama Y. 2009. Method for predicting the risk of drug-drug interactions involving inhibition of intestinal CYP3A4 and P-glycoprotein. Xenobiotica 39:430-443.
33. Burnier M, Brunner HR. 2000. Angiotensin II receptor antagonists. Lancet 355:637-645.
34. Scornik OA, Botbol V. 1997. Cellular uptake of 3H-bestatin in tissues of mice after its intravenous injection. Drug Metab Dispos 25:798-804.
35. Song JC, White CM. 2000. Pharmacologic, pharmacokinetic, and therapeutic differences among angiotensin II receptor antagonists. Pharmacotherapy 20:130-139.